Huadong Medicine Co Ltd
SZSE:000963

Watchlist Manager
Huadong Medicine Co Ltd Logo
Huadong Medicine Co Ltd
SZSE:000963
Watchlist
Price: 41.6 CNY -0.34%
Market Cap: 73B CNY

Huadong Medicine Co Ltd
Intangible Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Huadong Medicine Co Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Huadong Medicine Co Ltd
SZSE:000963
Intangible Assets
ÂĄ5.1B
CAGR 3-Years
29%
CAGR 5-Years
28%
CAGR 10-Years
34%
Sinopharm Group Co Ltd
HKEX:1099
Intangible Assets
ÂĄ8.8B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Intangible Assets
ÂĄ9.2B
CAGR 3-Years
14%
CAGR 5-Years
16%
CAGR 10-Years
16%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Intangible Assets
ÂĄ2.5B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
12%
C
China National Medicines Corp Ltd
SSE:600511
Intangible Assets
ÂĄ367m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
15%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Intangible Assets
ÂĄ463.3m
CAGR 3-Years
-12%
CAGR 5-Years
-9%
CAGR 10-Years
12%
No Stocks Found

Huadong Medicine Co Ltd
Glance View

Market Cap
73B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.

Intrinsic Value
52.65 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Huadong Medicine Co Ltd's Intangible Assets?
Intangible Assets
5.1B CNY

Based on the financial report for Sep 30, 2025, Huadong Medicine Co Ltd's Intangible Assets amounts to 5.1B CNY.

What is Huadong Medicine Co Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
34%

Over the last year, the Intangible Assets growth was 34%. The average annual Intangible Assets growth rates for Huadong Medicine Co Ltd have been 29% over the past three years , 28% over the past five years , and 34% over the past ten years .

Back to Top